Virus-like particles (VLPs) are of interest in vaccination, gene therapy and drug delivery, but
their potential has yet to be fully realized. This is because existing laboratory processes …

Virus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory
properties of natural viruses while omitting the infectious trait. VLPs that assemble from a …

Highlights▶ Microorganisms are inexpensive platforms to produce chimeric VLPs.▶
Bacteriophage-derived VLPs are excellent structures for drug delivery.▶ Microbial cell …

Over the last three decades, virus-like particles (VLPs) have evolved to become a widely
accepted technology, especially in the field of vaccinology. In fact, some VLP-based …

Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery.
Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous …

Virus-like particles (VLPs) structurally mimic the viral capsid and have therefore been
extensively, and quite successfully, used as vaccine and viral serology reagents. The ability …

Virus-like particles (VLPs) are nanoscale biological structures consisting of viral proteins
assembled in a morphology that mimic the native virion but do not contain the viral genetic …

As mimicking natural virus structures, virus‐like particles (VLPs) have evolved to become a
widely accepted technology used for humans which are safe, highly efficacious, and …

In recent years, the development of novel recombinant virus‐like particles (VLPs) has been
generating new perspectives for the prevention of untreated and arising infectious diseases …

Virus‐like particles (VLP) have received considerable attention for vaccine, drug delivery,
gene therapy and material science applications. Although the number of unique VLP and …